Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

• Главные авторы: Suvimol Niyomnaitham (Автор), Zheng Quan Toh (Автор), Patimaporn Wongprompitak (Автор), Laddawan Jansarikit (Автор), Kanjana Srisutthisamphan (Автор), Sompong Sapsutthipas (Автор), Yuparat Jantraphakorn (Автор), Natthakarn Mingngamsup (Автор), Paul V Licciardi (Автор), Kulkanya Chokephaibulkit (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and CoronaVac (Sinovac) in healthy adults, as well as booster response to BNT162b2 following heterologous CoronaVac and ChAdOx1 nCoV-19 re...